A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety
of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia,
Not Eligible for Standard Induction Therapy